S.1941 - Cure Hepatitis C Act of 2025 (119th Congress)
Summary
The Cure Hepatitis C Act of 2025 aims to eliminate hepatitis C virus (HCV) in the United States through a comprehensive program managed by the Secretary of Health and Human Services. The Act establishes the Hepatitis C Elimination Program, develops a national strategy and implementation plan, and creates advisory and interagency working groups. It also includes a subscription program for purchasing HCV treatments for specific populations, including those in correctional facilities, Medicaid/CHIP enrollees, individuals without minimum essential coverage, and those served by Indian Health Programs.
Expected Effects
The Act will likely increase access to hepatitis C treatment for vulnerable populations, reducing the prevalence of the virus and its associated health complications. It also aims to improve coordination among federal agencies and stakeholders in addressing HCV. The Act could also reduce healthcare costs associated with long-term complications of HCV.
Potential Benefits 4/5
- Increased access to hepatitis C treatment for vulnerable populations, including those incarcerated or lacking insurance.
- Improved public health outcomes through reduced HCV prevalence and related complications.
- Enhanced coordination among federal agencies and stakeholders in addressing HCV.
- Potential cost savings in the long term due to reduced healthcare expenses associated with chronic HCV infection.
- Focus on prevention, detection, and treatment strategies tailored to priority populations.
Potential Disadvantages
- The Act relies on significant federal funding, which may strain the budget.
- The program's success depends on effective implementation and coordination among various agencies and stakeholders.
- There may be challenges in reaching and engaging all eligible individuals, particularly those without stable housing or healthcare access.
- The Act's restrictions on using other federal drug discount programs could create administrative complexities.
- The program's focus on specific populations might inadvertently exclude other individuals in need of treatment.
Most Disadvantaged Areas:
Constitutional Alignment 4/5
The Act aligns with the Constitution's mandate to "promote the general Welfare" (Preamble) by addressing a significant public health issue. Congress has the power to legislate on matters related to interstate commerce (Article I, Section 8), which includes regulating healthcare and pharmaceutical industries. The Act's provisions for funding and establishing federal programs fall within Congress's enumerated powers.
Impact Assessment: Things You Care About
This action has been evaluated across 19 key areas that matter to citizens. Scores range from 1 (highly disadvantageous) to 5 (highly beneficial).